Kite Pharma Inc  

(Public, NASDAQ:KITE)   Watch this stock  
Find more results for NIHC, Inc.�
+0.96 (1.55%)
After Hours: 62.40 -0.57 (-0.91%)
Oct 6, 6:21PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 57.43 - 64.02
52 week 28.55 - 89.21
Open 61.62
Vol / Avg. 0.00/876,502.00
Mkt cap 2.71B
P/E     -
Div/yield     -
EPS -1.64
Shares 43.73M
Beta     -
Inst. own 82%
Nov 12, 2015
Q3 2015 Kite Pharma Inc Earnings Release (Estimated) Add to calendar
Aug 17, 2015
Kite Pharma Inc Corporate Update Call - Webcast
Aug 12, 2015
Kite Pharma Inc at Canaccord Genuity Growth Conference
Aug 10, 2015
Q2 2015 Kite Pharma Inc Earnings Call - Webcast
Aug 10, 2015
Q2 2015 Kite Pharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -474.49% -
Operating margin -498.73% -
EBITD margin - -
Return on average assets -17.54% -21.62%
Return on average equity -21.98% -22.73%
Employees 72 -
CDP Score - -


United States - Map
+1-310-8249999 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Company's lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.

Officers and directors

Arie S. Belldegrun M.D. Executive Chairman of the Board, President, Chief Executive Officer, Founder
Age: 65
Bio & Compensation  - Reuters
Cynthia M. Butitta Chief Financial Officer, Chief Operating Officer
Age: 60
Bio & Compensation  - Reuters
David D Chang M.D., Ph.D. Executive Vice President - Research and Development, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Helen S. Kim Executive Vice President - Business Development
Age: 52
Bio & Compensation  - Reuters
Margo R. Roberts Ph.D. Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Marc D. Better Ph.D. Vice President - Product Sciences
Age: 59
Bio & Compensation  - Reuters
Rizwana F. Sproule Vice President - Regulatory Affairs
Age: 52
Bio & Compensation  - Reuters
Jeffrey Wiezorek M.D. Vice President - Clinical Development
Age: 43
Bio & Compensation  - Reuters
David Bonderman J.D. Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
Franz B. Humer Ph.D. Director
Age: 69
Bio & Compensation  - Reuters